Wechselwirkungen · Cyramza
Cyramza 10 mg/ml concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 11
HOS-130129 · Präparat HOS-096857
No drug-drug interactions were observed between ramucirumab and paclitaxel. The pharmacokinetics of paclitaxel were not affected when co-administered with ramucirumab and the pharmacokinetics of ramucirumab were not affected when co-administered with paclitaxel. The pharmacokinetics of irinotecan and its active metabolite, SN-38, were not affected when co-administered with ramucirumab. The pharmacokinetics of docetaxel or erlotinib were not affected when co-administered with ramucirumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): docetaxel (HOS-084505) erlotinib (HOS-113527) paclitaxel (HOS-087959) irinotecan (HOS-112102)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T14:55:00Z · SHA-256 24154ea821ed10186fb564202f2c172a36dd6da94cb438714c99337075c53ca0 · Passage ff45a822a87db47ab861a5d5373e694bba5ca5aa46481542bdeaa7335f9dab72 · Zeichen 0–492 im Abschnitt